New study published in the new england journal of medicine demonstrates abbott's freestyle libre® 2 system has positive impacts on glucose levels and quality of life

Randomized clinical trial of abbott's freestyle libre 2 system compared to self-monitoring of blood glucose (smbg) shows freestyle libre 2 leads to significant reductions in glycated hemoglobin (hba1c) levels at 24 weeks in people with type 1 diabetes and sub-optimal glycemic control1 people using the freestyle libre technology had average hba1c levels a significant 0.5% lower than those using smbg at the end of the study period1 the freestyle libre 2 system use was also linked to improvements in overall satisfaction and reduced burden associated with glucose monitoring1 abbott park, ill., oct. 6, 2022 /prnewswire/ -- a new study published in the new england journal of medicine finds that for adults with type 1 diabetes and sub-optimal glycemic control, abbott's freestyle libre® 2 glucose monitoring system provided significant reductions in glycated hemoglobin (hba1c) compared to self-monitoring of blood glucose (smbg), which were sustained for the study duration of 24 weeks.1 use of the freestyle libre 2 system was also linked to improvements in participant-reported quality of life outcomes, including overall satisfaction and reduction in burden associated with glucose monitoring.
ABT Ratings Summary
ABT Quant Ranking